Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.54 |
| ▸ | CA2 | P00918 | 14/20 | 0.54 |
| ▸ | CA4 | P22748 | 7/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22461368 | 0.86 | RAB9A (0.46) | CA1CA2CA4CA12CA9 | |
| SCHEMBL15499792 | 0.81 | CA1 (0.75) | CA1CA2CA4CA12CA9 | |
| SCHEMBL22440670 | 0.80 | RAB9A (0.60) | CA1CA2RAB9AHPGDGAA | |
| SCHEMBL22440671 | 0.80 | RAB9A (0.60) | CA1CA2RAB9AHPGDGAA | |
| SCHEMBL22440676 | 0.80 | RAB9A (0.60) | CA1CA2RAB9AHPGDGAA | |
| SCHEMBL6047699 | 0.80 | CA1 (0.59) | CA1CA2CA4CA12CA9 | |
| SCHEMBL22440674 | 0.77 | MAPT (0.57) | CA1CA2RAB9AHPGDGAA | |
| SCHEMBL22440682 | 0.76 | POLB (0.67) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL4272357 | 0.75 | CA1 (0.67) | CA1CA2CA4CA12CA9 | |
| SCHEMBL4268752 | 0.75 | CA1 (0.67) | CA1CA2CA4CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200298194-A1 | ARAMID AMPHIPHILE SELF-ASSEMBLED NANOSTRUCTURES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200298194-A1 | ARAMID AMPHIPHILE SELF-ASSEMBLED NANOSTRUCTURES | ANXA6, ANXA1, ANXA11 | CA1 1888/4885CA2 3435/4885CA4 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.